|
| | Orelabrutinib Basic information |
| Product Name: | Orelabrutinib | | Synonyms: | :6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-Pyridinecarboxamide;Orelabrutinib;ICP-022;3-Pyridinecarboxamide, 6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-;Orelabrutinib USP/EP/BP;6-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide;Malignancies,Btk,ICP 022,inhibit,antineoplastic,Inhibitor,chronic,small,Bruton tyrosine kinase,lymphocytic leukemia,cell,Orelabrutinib,ICP022;Orelabrutinib (ICP-022) | | CAS: | 1655504-04-3 | | MF: | C26H25N3O3 | | MW: | 427.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1655504-04-3.mol |  |
| | Orelabrutinib Chemical Properties |
| Boiling point | 646.3±55.0 °C(Predicted) | | density | 1.213±0.06 g/cm3(Predicted) | | pka | 14.80±0.50(Predicted) |
| | Orelabrutinib Usage And Synthesis |
| Description | Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase with potential antineoplastic activity. | | Uses | Orelabrutinib has been previously approved to treat patients with relapsed or refractory (R/R) mantle cell lymphoma and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma. | | Biological Activity | Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). | | Mechanism of action | Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. | | target | |
| | Orelabrutinib Preparation Products And Raw materials |
|
